{"preliminary_commentary":{"by_channel":{"x_thread":109,"youtube":7,"podcast":6,"bluesky_thread":3,"x_video":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01730937\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"RTOG 1112","nct_id":"NCT01730937","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=rtog-1112-nct01730937. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"400 mg sorafenib twice a day for 28-day cycle. Continue up to 5 years in the absence of disease progression or unacceptable toxicity.","label":"Sorafenib Alone","type":"ACTIVE_COMPARATOR"},{"description":"27.5 Gy to 50 Gy stereotactic body radiation therapy (SBRT) in 5 fractions 24-72 hours apart over 5-15 days followed within 1-5 days by one cycle of 200 mg sorafenib twice a day. Starting with second cycle, if tolerable, increase to 400 mg sorafenib twice a day. Continue up to 5 years in the absence of disease progression or unacceptable toxicity.","label":"SBRT followed by Sorafenib","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)","NRG Oncology"],"completion_date":{"date":"2025-09-04","type":"ACTUAL"},"conditions":["Adult Primary Hepatocellular Carcinoma","Advanced Adult Primary Liver Cancer","Recurrent Adult Primary Liver Cancer"],"enrollment":{"count":193,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Sorafenib","otherNames":["BAY 43-9006","BAY 43-9006 Tosylate Salt","BAY 54-9085","Nexavar","SFN","Sorafenib Tosylate"],"type":"DRUG"},{"name":"stereotactic body radiation therapy","otherNames":["SBRT","stereotactic radiation therapy","stereotactic radiotherapy","stereotactic ablative body radiation therapy,","stereotactic ablative radiotherapy","SABR"],"type":"RADIATION"}],"last_update":"2026-01-28","lead_sponsor":"Radiation Therapy Oncology Group","official_title":"Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2022-07-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival","timeFrame":"From randomization to last follow-up: weekly during SBRT, post-SBRT/pre-sorafenib, monthly during sorafenib, and overall, from study entry: every 3 months for 2 years, then every 6 months. Maximum follow-up at time of analysis was 7.6 years."}],"references":[{"citation":"Dawson LA, Winter KA, Knox JJ, Zhu AX, Krishnan S, Guha C, Kachnic LA, Gillin MT, Hong TS, Craig TD, Williams TM, Hosni A, Chen E, Noonan AM, Koay EJ, Sinha R, Lock MI, Ohri N, Dorth JA, Delouya G, Swaminath A, Moughan J, Crane CH. Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2025 Feb 1;11(2):136-144. doi: 10.1001/jamaoncol.2024.5403.","pmid":"39699905","type":"DERIVED"}],"start_date":{"date":"2013-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer","url":"https://clinicaltrials.gov/study/NCT01730937"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/rtog-1112-nct01730937"}